Regadenoson Real Time Perfusion Imaging Trial-Optison
NCT01489176
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Coronary Artery Disease
Myocardial Perfusion Abnormalities
Interventions
DRUG:
Regadenoson; Optison
Sponsor
University of Nebraska
Collaborators
[object Object]
[object Object]